A Study Of PF-06647263 In Patients With Advanced Solid Tumors

Status: Recruiting
Phase: Phase 1
Diagnosis: Solid Tumor/Phase I
NCT ID: NCT02078752 (View complete trial on ClinicalTrials.gov)
DFCI Protocol ID:


To assess the safety and tolerability at increasing dose levels of PF-06647263 in patients with advanced solid tumors in order to determine the maximum tolerated dose and select the recommended Phase 2 dose.


Conducting Institutions:
Dana-Farber Cancer Institute, Brigham and Women's Hospital

Overall PI:
Ian Krop, MD, Dana-Farber Cancer Institute

Site-responsible Investigators:

Dana-Farber Cancer Institute: Andrew Wolanski, 617-632-6623, andrew_wolanski@dfci.harvard.edu

Eligibility Criteria

Inclusion Criteria: - Diagnosis of solid tumor that is advanced/metastatic and resistant to standard therapy or for whom no standard therapy is available - Performance Status of 0 or 1 - Adequate bone marrow, kidney, and liver function - Part 2 includes target expressing triple negative breast cancer or advanced epithelial ovarian cancer patients Exclusion Criteria: - Brain metastases requiring steroids - Major surgery, radiation therapy, or systemic anti-cancer therapy within 4 weeks of study treatment start - Active and clinically significant bacterial, fungal or viral infection
  • Email
  • Print
  • Share
  • Text
Highlight Glossary Terms
  • Make an Appointment

    • For adults:
      877-442-3324 (877-442-DFCI)

    • Quick access:
      Appointments as soon as the next day for new adult patients

    • For children:
      888-733-4662 (888-PEDI-ONC)

    • Make Appointment Online